Georg Pilz

Georg Pilz

Auto-generated profile, based on publicly available information

Georg Pilz

Department of Neurology, Neurocritical Care and Neurorehabilitation Christian Doppler University Hospital, Member of the European Reference Network EpiCARE, and Centre for Cognitive Neuroscience, Paracelsus Medical University Salzburg Austria

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAndrea Harrer
Andrea Harrer
GPGeorg Pilz
Georg Pilz
MEMax Einhaeupl
Max Einhaeupl
KOKatrin Oppermann
Katrin Oppermann
Wolfgang HitzlWolfgang Hitzl
Wolfgang Hitzl
JKJoerg Kraus
Joerg Kraus
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing- remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α4 subunit of very-late activation antigen-4 (VLA-4). Although well tolerated and very effective, some patients still suffer from relapses in spite of natalizumab therapy or from unwanted side effects like progressive multifocal leukoencephalopathy (PML). In search of a routine-qualified biomarker on the effectiveness of natalizumab therapy we applied flow cytometry and analyzed natalizumab binding to α4 and α4 integrin surface levels on T-cells, B-cells, natural killer (NK) cells, and NKT cells from 26 RRMS patients under up to 72 weeks of therapy. Four-weekly infusions of natalizumab resulted in a significant and sustained increase of lymphocyte-bound natalizumab (p<0.001) which was paralleled by a significant decrease in detectability of the α4 integrin subunit on all lymphocyte subsets (p<0.001). We observed pronounced natalizumab accumulations on T and B cells at single measurements in all patients who reported clinical disease activity (n = 4). The natalizumab binding capacity of in vitro saturated lymphocytes collected during therapy was strongly diminished compared to treatment-naive cells indicating a therapy-induced reduction of α4. Summing up, this pilot study shows that flow cytometry is a useful method to monitor natalizumab binding to lymphocytes from RRMS patients under therapy. Investigating natalizumab binding provides an opportunity to evaluate the molecular level of effectiveness of natalizumab therapy in individual patients. In combination with natalizumab saturation experiments, it possibly even provides a means of studying the feasability of patient-tailored infusion intervals. A routine-qualified biomarker on the basis of individual natalizumab saturation on lymphocyte subsets might be an effective tool to improve treatment safety.

18 June 2025 in Epileptic Disorders
Verified
Journal Article
Open access
MLMarkus Leitinger
Markus Leitinger
PVPILAR BOSQUE VARELA
PILAR BOSQUE VARELA
GKG. Kuchukhidze
G. Kuchukhidze
ULU. Leitner
U. Leitner
JHJ. Höfler
J. Höfler
ETEugen Trinka
Eugen Trinka
Status epilepticus (SE) can be regarded as the most severe expression of seizure activity characterized by a low probability of spontaneous cessation and mechanisms leading to metabolic and inflammatory derangements with increased risk of brain damage, alterations of neural networks, and potentially life‐threatening systemic complications. Time‐based criteria are fundamental in diagnosing SE as response to treatment and outcomes worsen with increasing duration in terms of neurological impairment and mortality. Classification of status epilepticus includes four axes: semiology, EEG correlates, etiology, and age. Semiology, especially when evolving from SE with prominent motor phenomena (SE‐PM) to nonconvulsive status epilepticus (NCSE) with impaired consciousness, is associated with drug resistance and poor prognosis. The Salzburg EEG criteria define four subcategories of NCSE. The umbrella term ictal‐interictal continuum (IIC) includes a wide spectrum of EEG changes ranging from almost non‐epileptic situations to conditions that just fail to fulfill the criteria of NCSE. From a pathophysiologic point of view, EEG patterns on the IIC might be generated by both the underlying etiology and the superimposed hypersynchronous epileptic activity. It is impossible to disentangle their relative contributions by visual inspection of the EEG. However, it is essential to identify the contribution of ictal activity in an individual patient as it may be amenable to treatment with antiseizure medication (ASM). The main approach is to perform a diagnostic intravenous ASM trial (diagnostic IV‐ASM trial) during EEG recording and to assess for both EEG and clinical response. Furthermore, CT‐ and MRI‐perfusion studies help to clarify the diagnosis. Early and consequent treatment is necessary to minimize the total time spent in status, also called seizure burden. This educational review focuses on the diagnosis of status epilepticus in children and adults, excluding neonatal status.

1 October 2013 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PDF file
GPG. Pilz
G. Pilz
AHAndrea Harrer
Andrea Harrer
PWPeter Wipfler
Peter Wipfler
KOK. Oppermann
K. Oppermann
JSJohann Sellner
Johann Sellner
ETEugen Trinka
Eugen Trinka

26 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
TMTobias Moser
Tobias Moser
MSMichael Seiberl
Michael Seiberl
JFJulia Feige
Julia Feige
LBLara Bieler
Lara Bieler
RRRichard F. Radlberger
Richard F. Radlberger
PWPeter Wipfler
Peter Wipfler
Background: Efficacy of vaccines and disease activity linked to immunization are major concerns among people with multiple sclerosis (pwMS).Objective: To assess antibody responses to seasonal influenza antigens and vaccine-associated neuroaxonal damage utilizing serum neurofilament light chain (sNfL) in pwMS receiving dimethyl fumarate (DMF).Methods: In this prospective study, the 2020/2021 seasonal tetravalent influenza vaccine was administered to 20 pwMS treated with DMF and 15 healthy controls (HCs). The primary endpoints were responder rate of strain-specific antibody production (seroconversion or significant (4-fold) increase in influenza-antibody titers for ≥2/4 strains) at 30 days post-vaccination and changes in sNfL levels.Results: All patients treated with DMF fulfilled the responder criteria for immunization compared with 53% of the controls. However, higher proportions of HCs already had influenza-antibody titers ≥1:40 at baseline (53% vs. 41%, p = 0.174). sNfL levels were comparable among both groups at baseline and did not increase 34 days after vaccination. In addition, no clinical or radiological disease reactivation was found.Conclusion: DMF-treated patients mount an adequate humoral immune response to influenza vaccines. Within the limits of the small cohort investigated, our data suggest that influenza immunization is not associated with clinical or subclinical disease reactivation.

12 February 2013 in Neurology
Verified
Journal Article
Closed access
JKJorg Kraus
Jorg Kraus
GPGeorg Pilz
Georg Pilz
PWPeter Wipfler
Peter Wipfler
KOKatrin Oppermann
Katrin Oppermann
BHBarbara Holl
Barbara Holl
AHAndrea Harrer
Andrea Harrer

16 June 2026 in Epileptic Disorders
Verified
Journal Article
Open access
GBGemma Bassani
Gemma Bassani
TMTobias Moser
Tobias Moser
LMLukas Machegger
Lukas Machegger
FRFabio Rossini
Fabio Rossini
GPGeorg Pilz
Georg Pilz
GKGiorgi Kuchukhidze
Giorgi Kuchukhidze